CD289 Antibody [72-1665] (PE)

Product Specifications

Background

The 72-1665 monoclonal antibody specifically reacts with CD289, also known as human toll-like receptor 9 (TLR9) . CD289 is involved in the activation of innate immunity, in acquired immune responses, and autoimmune diseases. It is involved in the immune system’s response to unmethylated CpG dinucleotide sequences such as those found in bacterial, viral, or synthetic DNA. CD289 assists in pathogen recognition and is expressed by subtypes of dendritic cells and B cells.

NCBI Gene ID

54106

Swiss Prot

Q9NR96

Host

Rat

Reactivity

Human

Clonality

Monoclonal

Clone

72-1665

Conjugation

Type

Primary Antibodies

Field of Research

Innate Immunity

Purification

The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.

Concentration

Batch dependent

Buffer

Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

The product should be stored undiluted at 4˚ C and should be protected from prolonged exposure to light. Do not freeze.

Fragment

Rat IgG2a, kappa

Specificity

The 72-1665 monoclonal antibody specifically reacts with CD289, also known as human toll-like receptor 9 (TLR9) .

Symbol

TLR9

NCBI Official Name

Toll-like receptor 9

NCBI Organism

Homo sapiens

Background Reference 01

Zhang, J. Y., Zhang, Z., Wang, X., Fu, J. L., Yao, J., Jiao, Y., ... Wang, F. S. (2007) . PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors.Blood,109 (11), 4671-4678.

Background Reference 02

Bennett, F., Luxenberg, D., Ling, V., Wang, I. M., Marquette, K., Lowe, D., ... Carreno, B. M. (2003) . Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.The Journal of Immunology,170 (2), 711-718.

Background Reference 03

Thompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., Kwon, E. D. (2007) . PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.Clinical Cancer Research,13 (6), 1757-1761.